SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-060712
Filing Date
2024-03-06
Accepted
2024-03-06 16:05:18
Documents
15
Period of Report
2024-03-06
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d807709d8k.htm   iXBRL 8-K 37022
2 EX-99.1 d807709dex991.htm EX-99.1 8481
  Complete submission text file 0001193125-24-060712.txt   175064

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amam-20240306.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE amam-20240306_lab.xml EX-101.LAB 17977
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amam-20240306_pre.xml EX-101.PRE 11253
16 EXTRACTED XBRL INSTANCE DOCUMENT d807709d8k_htm.xml XML 3639
Mailing Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037
Business Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037 (858) 875-2400
Ambrx Biopharma, Inc. (Filer) CIK: 0001990550 (see all company filings)

IRS No.: 932892120 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-56600 | Film No.: 24725849
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)